Prophylactic human papillomavirus vaccines: 2008 Consensus document;Vacunas profilácticas frente al virus del papiloma humano: Documento de consenso 2008

Semergen

Volumn 35, Issue 1, 2009, Pages 20-28

  Cortes Bordoya J ^l   Garcia De Paredesb M ^a   Munoz Zatoc E ^b   Martinon Torresd F ^c   Torne Bladee A ^d   Garcia Rojasf A ^e   Cisterna Cancerg, R ^f   Vidart Aragonh J A ^g   Abizanda Gonzalezi M ^h   Pipoll Lozanoj, M A ⁱ   Vilaplana Vilaplanak, E ^j   Poveda Velascol, A ^k  

^a Asociacion Espanola Contra el Cancer   (Spain)

^b Academia Española de Dermatología y Venereología AEDV   (Spain)

^c Hospital Clínico   (Spain)

^d Asociación Española de Patología Cervical y Colposcopia AEPCC   (Spain)

^e Asociación Española de Vacunología AEV   (Spain)

^f Asociación de Microbiología y Salud AMYS   (Spain)

^g Sociedad Española de Ginecología y Obstetricia SEGO   (Spain)

^h Sociedad Española de Médicos de Atención Primaria SEMERGEN   (Spain)

ⁱ Sociedad Española de Médicos Generales Y de Familia SEMG   (Spain)

^j Instituto Bernabeu   (Spain)

^k INSTITUTO VALENCIANO DE ONCOLOGÍA   (Spain)

^l NONE

more..

Author keywords

Epstein Barr virus; Infectious mononucleosis; Spleen

Indexed keywords

EID: 77956621648     PISSN: 11383593     EISSN: 15788865     Source Type: Journal    
DOI: 10.1016/S1138-3593(09)70178-9     Document Type: Article

References (71)

1. Burchell AN,Winer RL, De Sanjosé S, Franco E. Epidemiology and transmission dynamics of genital HPV infection. Vaccine. 2006;24 Suppl 3:52-61.
2. Baseman JG, Koutsky LA.The epidemiology of human Papillomavirus infections. J Clin Virol. 2005;Suppl 1:S16-24.
3. Zur Hausen H. Papillomaviruses and cancer: from basic studies to clinical application. Nat Res Cancer. 2002;2:342-350
4. 4. Muñoz N, Castellsagué X, Berrington de González A, Gissmann L. HPV in the etiology of human cancer. Vaccine. 2006;24 Suppl 3:1-10.
5. Bosch FX, Lorincz A, Muñoz N, Meijer CJL, Shah KV. The casual relation between human papillomavirus and cervical cancer. J Clin Pathol. 2002;55:244-265
6. Castellsagué X, Díaz M, De Sanjosé S, Muñoz N, Herrero R, Franceschi S, et al. Worldwide human Papillomavirus etiology of cervical adenocarcinoma and its cofac-tors: implications for screening and prevention. J Natl Cancer Inst. 2006;98:303-315
7. Parkin DM, Bray F. The burden of HPV-related cancers. Vaccine.2006;24 Supl 3:11-25.
8. Smith J, Lindsay L, Hoots B, et al. HPV type distribution in invasive cervical cancer and high-grade cervical lesions: A meta-analysis up-date. Int J Cancer. 2007;121:621-632
9. De Sanjosé S. Comunicación personal.
10. Ferlay J, Bray F, Pisan P, Parkin DM. GLOBOCAN 2002. Cancer incidence, mortality and prevalence worldwide. IARC CancerBase n.o 5, Version 2.0. Lyon: IARC Press; 2004.
11. a Monografía de la Sociedad Española de Epidemiología.Madrid: Sociedad Española de Epidemiología; 2006. p. 15-29.
12. Bosch, FX. HPV contribution and genotype distribution in invasive cancer of the vulva and the vagina in 14 countries. Comunicación PA2-06 a 24th International Papillomavirus Conference, Beijing, 3-9 de noviembre de 2007.
13. Kjaer SK, Tran TN, Sparen P, Tryggvadottir L, Munk C, Dasbach E, et al. The burden of genital warts: A study of nearly 70.000 women from the general population in the 4 Nordic Countries. J Infect Dis.2007;196:1447-1454
14. Castellsagué X, Cohet C, Puig Tintoré l, et al. Burden of genital warts in Spain. Comunicación FC1-2 a Eurogin 2007. Montecarlo, 2-5 de octubre.
15. De Sanjosé S, Diaz M, Castellsagué X, Clifford G, Bruni L, Muñoz N, et al. Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis. Lancet Infect Dis. 2007;7:453-459
16. Helen T. Duration of type-specific HPV infection: Results from the Ludwig-McGill Cohort Study. Comunicación a 23rd International Papillomavirus Conference. Praga, 1-7 de septiembre de 2006.
17. Khan MJ, Castle PE, Lorincz AT, Wacholder S, Sherman M, Scott DR, et al. Theelevated 10-year risk of cervical precancer and cancer in women with HPV type 16 or 18 and the possible utility of type- specific HPV testing in clinical practice. J Natl Cancer Inst. 2005;97:1072-1079
18. Partridge JM. The Natural History of Genital HPV Infection in Men.Comunicación a 23rd International Papillomavirus Conference.Praga, 1-7 de septiembre de 2006.
19. Informe global de la U.S. Preventive Services Task Force (USPSTF), abril 2006. Disponible en: http://wwww.ahrq.gov/clinic/3rduspstf/ cervcan/cervcanrr/. htm?linica
20. Cuzick J, Clavel C, Petry KU, Meijer CJ, Hoyer H, Ratnam S, et al. Overview of the European and North American studies on HPV testing in primary cervical screening. Int J Cancer. 2006;119:1095-1101
21. Mayrand MH, Duarte-Franco E, Rodrigues I, Walter SD, Hanley J, Ferenczy A, et al. Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer. N Engl J Med.2007;357:1579-1588
22. Pak SC, Martens M, Bekkers R, Crandon AJ, Land R, Nicklin JL, et al. Pap smear screening history of women with squamous cell carcinoma and adenocarcinoma of the cervix. Aust N Z J Obstet Gynaecol.2007;47:504-507
23. Bray F, Carstensen B, Moller H, Zappa M, Zakelj MP, Lawrence G, et al. Incidence trends of adenocarcinoma of the cervix in 13 European Countries. Cancer Epidemiol Biomarkers Prev. 2005;14:2191-2199
24. Cortés J. Estrategias de cribado del cáncer de cuello uterino. Prog Obstet Gynecol. 2005;48 Supl 1:228-230
25. De Sanjosé S. Historia de cribado en mujeres con cáncer infiltrante de cuello uterino. Gac Sanit. 2006;20:166-170
26. Cortés J. Potencial preventivo a corto plazo de la vacuna VPH.Impacto sobre los resultados citológicos anómalos. Disponible en: http://www.aepcc.org
27. Roberts JM, Thurloe JK. Comparative sensitivities of ThinPrep and Papanicolaou smear for adenocarcinoma in situ (AIS) and combined AIS/high-grade squamous intraepithelial lesion (HSIL): comparison with HSIL. Cancer. 2007;111:482-486
28. Garnett GP, Kim JJ, French K, Goldie SJ. Chapter 21: Modelling the impact of HPV vaccines on cervical cancer and screening programmes.Vaccine. 2006;24 Suppl 3:178-186
29. Nieminen P, Kotaniemi-Talonen L, Hakama M, Tarkkanen J, Martikainen J, Toivonen T, et al. Randomized evaluation trial on automation- assisted screening for cervical cancer: results after 777,000 invitations. J Med Screen. 2007;14:23-28
30. Puig Tintoré LM, Cortés J, Castellsagué X, et al. Prevención del cáncer de cuello uterino ante la vacunación frente al virus del papiloma humano. Prog Obstet Ginecol. 2006;49 Supl 2:5-62.
31. Naucler. Human papillomavirus and Papanicolaou tests to screen for cervical cancer. N Engl J Med. 2007;357:1589-1597
32. a Monografía de la Sociedad Española de Epidemiología. Madrid: Sociedad Española de Epidemiología; 2006.
33. Franco EL, Cuzick J, Hildesheim A, De Sanjosé S. Issues in planning cervical cancer scre-ening in the era of HPV vaccination. Vaccine.2006;24 Suppl 3:171-177
34. o semestre de 2006.
35. Puig-Tintoré LM, Castellsagué X, Torné A, De Sanjosé S, Cortés J, Roura E, et al. Coverage and factors associated with cervical câncer screening: Results from the AFRODITA study, apopulation-based survey in Spain. J Low Genit Tract Dis. 2008;12:82-89
36. Tasca RA, Clarke RW. Recurrent respiratory papillomatosis. Arch Dis Child. 2006;91:689-691
37. Villa LL, Costa RL, Petta CA, Andrade RP, Paavonen J, Iversen OE, et al. High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18L1 virus-like particle vaccine through 5 years of follow-up. Br J Cancer. 2006;95:1459-1466
38. Harper DM, Franco EL, Wheeler CM, Moscicki AB, Romanowski B, Roteli-Martins CM, et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial.Lancet. 2006;367:1247-1255
39. Block SL, Nolan T, Sattler C, Barr E, Giacoletti KE, Marchant CD, et al. Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in male and female adolescents and young adult women. Pediatrics. 2006;118:2135-2145
40. Olsson SE, Villa LL, Costa RL, Petta CA, Andrade RP, Malm C, et al. Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18L1 virus-like particle (VLP) vaccine. Vaccine. 2007; 25:4931-4939
41. Stanley M. Understanding L1 VLP Vaccine: Immune response, immune memory and disease prevention. Ponencia al 20th European Board & College of Obstetrics and Gynaecology (EBCOG). Lisboa, 5-7 de marzo de 2008.
42. Garland SM, Steben M, Hernández-Ávila M, Koutsky LA, Wheeler CM, Pérez G, et al. Noninferiority of antibody response to human papillomavirus type 16 in subjects vaccinated with monovalent and quadrivalent L1 virus-like particle vaccines. Clin Vaccine Immunol.2007;14:792-795
43. Giannini SL, Hanon E, Moris P, Van Mechelen M, Morel S, Dessy F.Enhanced humoral and memory B cellular immunity using HPV16/ 18L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only. Vaccine.2006;24:5937-5949
44. Pedersen C, Petaja T, Strauss G, Rumke HC, Poder A, Richardus JH, et al. Immunization of early adolescent females with human papillomavirus type 16 and 18L1 virus-like particle vaccine containing AS04 adjuvant. J Adolesc Health. 2007;40:564-571
45. Schwarz TF, Dubin GO; for the HPV Vaccine Study Investigators for Adult Women, GlaxoSmithKline Biologicals. An AS04-containing human papillomavirus (HPV) 16/18 vaccine for prevention of cervical cancer is immunogenic and well-tolerated in women 15-55 years old. J Clin Oncol. 2006;24 Suppl 18:1008.
46. Dessy F. Evaluation of HPV neutralizing antibodies from an extended follow up study through 5,5 years in women vaccinated with GSKs prophylactic Cervical Cancer Candidate Vaccine. Comunicación 5B-01 a 24th International Papillomavirus Conference. Beijing, 3-9 de noviembre de 2007.
47. Pagliusi SR, Aguado MT. Efficacy and other milestones for human papillomavirus vaccine introduction. Vaccine. 2004;23:569-578
48. Koutsky L; for the FUTURE II Study Group. Quadrivalent vaccine against human papi-llomavirus to prevent high-grade cervical lesions.N Engl J Med. 2007;356:1915-1927
49. Ault KA; for the Future II Study Group. Efficacy of a prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials. Lancet 2007;369:1861-1868
50. Garland SM, Hernández-Ávila M, Wheeler CM, Pérez G, Harper DM, Leodolter S, et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med.2007;356:1928-1943
51. Paavonen J, Jenkins D, Bosch FX, Naud P, Salmerón J, Wheeler CM, et al. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double- blind, randomised controlled trial. Lancet. 2007;369:2161-2170
52. 52.Dillner J. Efficacy of quadrivalent HPV vaccination against condylomata and low-grade cervical, vulvar, and vaginal intraepithelial neoplasias. Presented at the 24th International Papillomavirus Conference and Clinical Workshop (IPCCW). Beijing, 3-9 de noviembre de 2007. Oral presentation 5B-04.
53. The Future II Study Group. Prophylactic efficacy of a quadrivalent human Papillomavirus (HPV) vaccine in women with virological evidence of HPV infection. J Infect Dis. 2007;196:1438-1446
54. Luna J, Saah A, Hood S, Barr E. Safety, efficacy and immunogenicity of quadrivalent HPV vaccine (Gardasil™) in women aged 24-45. Comunicación a 24th International Papillomavirus Congress. Beijing, 3-9 de noviembre de 2007.
55. Hildesheim A, Herrero R, Wacholder S, Rodríguez AC, Solomon D, Bratti MC. Effect of human papillomavirus 16/18L1 viruslike particle vaccine among young women with preexisting infection: a randomized trial. JAMA. 2007;298:743-753
56. Siegrist CA, Lewis EM, Eskola J, Evans SJ, Black SB. Human papilloma virus immunization in adolescent and young adults: a cohort study to illustrate what events might be mistaken for adverse reactions.Pediatr Infect Dis J. 2007;26:979-984
57. Markowitz LE, Dunne EF, Saraiya M, Lawson HW, Chesson H, Unger ER; Centers for Disease Control and Prevention (CDC); Advisory Committee on Immunization Practices (ACIP). Quadrivalent Human Papillomavirus Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2007;56(RR-2):1-24.
58. CDC Recommended inmunization schedules for persons aged 0-18 years. United States, 2007. MMWR. 2007;55:Q1-Q4. Disponible en: http://www.cdc.gov/ mmwr/preview/mmwrhtml/mm551a7.htm
59. Doc. Ref. EMEA / CHMP / 274938, London, 27 de julio 2006.
60. Doc. Ref. EMEA / CHMP/ 318931, London, 25 de julio 2007.
61. Brown DR. Quadrivalent HPV type 6, 11, 16, 18L1 VLP Vaccine: Updated 4 year analysis of cross-protection against CIN2/3 AIS caused by oncogenic HPV types in addition to 16/18. Comunicación P5B-02 a 24th International Papillomavirus Conference. Beijing, 3-9 de noviembre de 2007.
62. Joura EA, Leodolter S, Hernández-Ávila M, Wheeler CM, Pérez G, Koutsky LA, et al. Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomised clinical trials. Lancet. 2007;369:1693-1702
63. Frisch M, Biggar RJ, Goedert JJ. Human papillomavirus-associated cancers in patients with human immunodeficiency virus infection and acquired immunodeficiency syndrome. J Natl Cancer Inst.2000;92:1500-1510
64. Kim JJ, Andres-Beck B, Goldie SJ. The value of including boys in an HPV vaccination pro-gramme: a cost-effectiveness analysis in a low-resource setting. Br J Cancer. 2007;97:1322-1328
65. Palefsky JM, Gillison ML, Strickler HD. Chapter 16: HPV vaccines in immunocompro-mised women and men. Vaccine. 2006;24 Suppl 3:140-146
66. Roden R. Reemplazo de genotipos del VPH tras la vacunación. HPV Today. 2007 (ed. esp.);11:8-9.
67. Goldie SJ, Kohli M, Gruma D, Weinstein MC, et al. Projected clinical benefits and cost-efffectiveness of a human papillomavirus 16/18 vaccine. J Natl Cancer Inst. 2004;96:604-615
68. Kulasingam SL, Pagliusi S, Myers E. Potential effects of decreased cervical cancer screening participation after HPV vaccination: an example from the U.S. Vaccine. 2007;25:8110-8113
69. Brinkmann D, Gladman MA, Norman S, Lawton FG. Why do women still develop cancer of the cervix despite the existence of a national screening programme? Eur J Obstet Gynecol Reprod Biol.2005.
70. López J, Cortés J, Gil A. Estudio de coste-efectividad de la vacuna tetravalente del papiloma humano. Rev Esp Econ Salud. 2007;6:400-408
71. Investing in Health for Economic Development. Report of the Comission on Macroeconomics and Health. Geneva: WHO; 2001